文献速递类风湿关节炎

乌帕替尼治疗日本csDMARDs应答不佳类风湿关节炎5年安全性与疗效

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial.
PubMed 文献 · RMD Open · 2025-11-04

SELECT-SUNRISE随机对照试验评估乌帕替尼7.5、15、30 mg每日一次治疗日本中重度活动性类风湿关节炎且对稳定剂量csDMARDs应答不佳患者的5年安全性与疗效。长期扩展阶段121/187(64.7%)患者完成研究,不良事件类型与频率与第84周及其他乌帕替尼研究相当,15和30 mg组不良事件、严重不良事件、感染和严重感染发生率数值上高于7.5 mg组。第260周临床结局改善并维持,5年CDAI临床缓解率(NRI)在7.5、15、30 mg组分别为40.8%、26.5%、28.0%,未发现新安全信号。

要点

  • 121/187(64.7%)进入长期扩展阶段患者完成研究,安全性评估至第260周。
  • 15和30 mg组不良事件、严重不良事件、感染和严重感染发生率数值上高于7.5 mg组。
  • 5年CDAI临床缓解率(NRI)7.5 mg组40.8%、15 mg组26.5%、30 mg组28.0%。

核心结论

  • 乌帕替尼治疗5年显示持续疗效,未发现新安全信号,是日本csDMARDs应答不佳类风湿关节炎患者的长期治疗选择。

研究设计与样本

  • SELECT-SUNRISE双盲随机对照试验:日本患者随机接受乌帕替尼7.5、15或30 mg每日一次或安慰剂治疗12周,完成安慰剂对照期后进入长期扩展阶段继续原剂量或由安慰剂切换至乌帕替尼7.5、15或30 mg每日一次;盲法维持至乌帕替尼30 mg切换至15 mg(最早切换在第132周);安全性与疗效评估至第260周。

主要发现

  • 进入长期扩展阶段的187例患者中121例(64.7%)完成研究。
  • 不良事件的类型和频率与第84周报告及其他乌帕替尼研究相当。
  • 任何不良事件、严重不良事件、感染和严重感染的发生率在乌帕替尼15和30 mg组数值上高于7.5 mg组。
  • 临床结局改善并维持至第260周。
  • 5年时CDAI临床缓解率(非应答者填补)在乌帕替尼7.5、15、30 mg组分别为40.8%、26.5%、28.0%。

临床怎么用

  • 乌帕替尼7.5、15、30 mg每日一次治疗日本csDMARDs应答不佳类风湿关节炎患者5年显示持续疗效且未发现新安全信号。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the long-term safety and efficacy of upadacitinib over 5 years in Japanese patients with moderate-to-severe active rheumatoid arthritis and an inadequate response to stable doses of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs-IR). METHODS: Japanese patients received upadacitinib 7.5, 15 or 30 mg once per day or placebo for 12 weeks in a double-blind, randomised manner. Patients who completed the placebo-controlled phase entered a long-term extension phase during which they continued the same upadacitinib dose or were switched from placebo to upadacitinib 7.5, 15 or 30 mg once per day. Blinding was maintained until dose switching from upadacitinib 30 mg to 15 mg, prior to the regulatory approval of 15 mg; the earliest switch occurred at week 132. Safety and efficacy were evaluated through week 260. RESULTS: In total, 121/187 (64.7%) patients who entered the long-term extension phase completed the study. The types and frequency of adverse events were comparable with those reported at week 84 and in other studies of upadacitinib. The incidences of any adverse events, serious adverse events, infection and serious infection were numerically higher on upadacitinib 15 and 30 mg than on 7.5 mg. Clinical outcomes were improved and maintained over 260 weeks; Clinical Disease Activity Index clinical remission rates after 5 years were 40.8%, 26.5% and 28.0% on upadacitinib 7.5, 15 and 30 mg, respectively (non-responder imputation). CONCLUSIONS: Upadacitinib showed sustained efficacy with no new safety signals identified through 5 years of treatment and is a long-term treatment option for Japanese patients with rheumatoid arthritis and csDMARDs-IR.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kameda H, Takeuchi T, Yamaoka K, et al. Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial. RMD Open. 2025. PMID: 41193232. doi:10.1136/rmdopen-2025-006213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。